Ruth Wexler is an American industrial chemist best known as a co-discoverer of apixaban, a marketed anticoagulant; and losartan, a blood pressure treatment.[1]
Ruth R. Wexler | |
---|---|
Born | Pikesville, MD |
Nationality | American |
Alma mater | University of Pennsylvania |
Known for | cardiovascular drug development |
Scientific career | |
Thesis | (1982) |
Doctoral advisor | Amos Smith |
Wexler received her B.A. in chemistry from Boston University in 1977, and a Ph.D. in organic chemistry working with Amos B. Smith at the University of Pennsylvania in 1982.[2][3]
Wexler started her career at DuPont in 1982, rising to Executive Director in 1998. She then joined Bristol-Myers Squibb as an Executive Director in 2001, moving eventually to New Jersey to head their cardiovascular research unit.[2] She has worked on targets involved in apoptosis, inflammation, obesity, and coagulation. As of 2018, she has over 215 original research publications.[4]